P1: PSB Printer: Yet To Come
9780521704632ind CUFX213A/Peck 9780521618168 December 29, 2007 17:19
375 Indexpotassium ions, conductance during action
potential,164f
potassium-sparing diuretics, 306 –308
potentiation drug interactions, 43
Poynting effect, 121
prazosin, 219 –220
effects, 219 –220
kinetics, 220
presentation, 219
uses, 219
prednisolone, 45 , 353
perioperative supplementation, 355
pregabalin, 281
pregnalolone, 102 –103
intravenous anaesthesia, 102 –103
pregnancy, drugs during, 16
prilocaine,173t
intravenous regional anaesthesia, 168
probenecid, 43 , 313
procainamide, 241 –242
kinetics, 242
mechanism of action, 241
side-effects, 241 –242
uses, 241
prochlorperazine, 285
pro-drugs, 17
promethazine, 290
propafenone, 243 –244
propionic acid, 97
propofol, 80 –81, 108, 110t, 282
Bristol model of TIVA, 81 –82
clearance, 74
co-administration with midazolam, 42
context sensitive half-time, 77 –78
effects, 108
GABAAreceptors, 101 –102
hepatocyte uptake rate, 11
kinetics,110t
pharmacokinetics, 80
presentation, 108
structure, 80
target-controlled infusion pumps, 82 –84
toxicity,110t
uses, 108
volume of distribution, 72
propranolol,225t, 226t, 357
proprionic acids, 158
propylthiouracil, 357
prostacyclin (PGI 2 ), 335–336, 339
prostaglandins, 149 –151
analogues, 296 –297
synthesis,150f
protamine, 342
protein binding, 7
barbiturates,104tcephalosporins, 315 –316
drug interactions, 41
drugs with high level, 11
drugs with low level, 11
fetal, 15 –16
lipophilic nature of sites, 99 –100
local anaesthetics, 165 , 167–168
maternal, 15 –16
neonates, 22 –23
prothrombin time, 22 , 344
proton acceptors,5–6
proton donors,5–6
proton pump inhibitors, 294 –295
pseudomembranous colitis, 313 , 324
purinergic receptors, ionotropic, 26
purines, 86
Px1 and Px2 receptors, 26
pyloric stenosis, 299
pyrazole, 97
pyrazolones, 97 , 157–158
pyridostigmine, 193 –195
pyrimidines, 86
quinidine, 236 –237
drug interactions, 236 –237
kinetics, 237
mechanism of action, 236
side-effects, 236 –237
quinolones, 320 –321
kinetics, 321
mechanism of action, 321
side-effects, 321
quinols, 97racemic mixtures, 48
ramipril, 260
ranitidine, 41 –42, 293–294
receptors, 25 , 27f, 31
agonism, 33 –34
allosteric modulation of binding,
37 –38
altered ion permeability, 25 –26
antagonism, 35 –38
classes, 25 –26
drug binding dynamics, 31 –32
drug interaction types, 32 –38
general anaesthetic effects,101t
metabotropic interactions, 26 –27
spare, 38
rectal route, 11
rectangular hyperbola,55f, 56f
reduction, 17 –18
re-entry mechanisms, 229
regional anaesthesia, intravenous,
168